Glaxosmithkline Share News (GSK)

TOP NEWS: GSK sues Pfizer over patent infingements for RSV vaccine

(Alliance News) - GSK PLC on Wednesday sued Pfizer Inc over patent infringement, alleging Pfizer's respiratory syncytial virus vaccine steals key elements of GSK's version.

GSK sues Pfizer in US for patent infringement over RSV vaccine

Aug 2 (Reuters) - British biopharmaceutical giant GSK sued Pfizer in a U.S. court on Wednesday, alleging that Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violates GSK's patent rights in its rival RSV shot Arexvy.

GSK sues Pfizer in US for patent infringement over RSV vaccine

Aug 2 (Reuters) - British biopharmaceutical giant GSK sued Pfizer in Delaware federal court on Wednesday, accusing Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo of violating GSK's patent rights in its rival RSV shot Arexvy.

Sensodyne maker Haleon's shiny forecast signals price hikes unlikely to dent demand

Shares down 1% on slight decline in H1 adj operating margin

*

TOP NEWS: Haleon boosts annual guidance after solid first half

(Alliance News) - Haleon PLC on Wednesday upped its annual organic revenue growth guidance following a solid revenue performance in the first half of 2023.

IN BRIEF: GSK hails US FDA approval for cancer treatment, Jemperli

GSK PLC - London-based pharmaceutical company - Jemperli plus chemotherapy approved in the US by the Food & Drug Administration as the first new frontline treatment option in decades for primary advanced or recurrent endometrial cancer. Notes Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy. Hesham Abdullah, senior vice president and global head of oncology development at GSK, says: "Today's approval underscore our belief in the potential for Jemperli to transform cancer treatment as a backbone immuno-oncology therapy."

DIRECTOR DEALINGS: Qinetiq, Tesco and GSK executives sell shares

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced late last week and not separately reported by Alliance News:

LONDON BROKER RATINGS: Oddo BHF raises IAG to 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

GSK raises 2023 outlook boosted by vaccine, HIV drug sales

Q2 sales and earnings beat estimates

*

TOP NEWS: GSK raises annual guidance on quarterly earnings growth

(Alliance News) - GSK PLC on Wednesday upgraded its full-year guidance, after seeing a strong quarterly performance on the strength of segments like HIV and Vaccines.

GSK lifts full-year guidance after 'excellent' Q2

(Sharecast News) - GSK lifted its full-year guidance on Wednesday after an "excellent" second quarter.

GSK says HIV prevention drug recommended for marketing in Europe

(Alliance News) - GSK PLC on Monday said ViiV Healthcare's cabotegravir for HIV prevention has received a positive opinion by the European Medicines Agency for marketing authorisation.

GSK's ViiV gets Europe nod for HIV prophylaxis

(Sharecast News) - Pharmaceuticals giant GSK announced on Monday that its majority-owned HIV specialist subsidiary ViiV Healthcare has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending marketing authorisation for 'cabotegravir' long-acting (LA) injectable and tablets for HIV prevention.

Bavarian Nordic ends RSV vaccine programme after poor trial results

July 22 (Reuters) - Denmark-based Bavarian Nordic said on Saturday it was ending its respiratory syncytial virus (RSV) vaccine programme as its Phase 3 clinical trial did not meet all the primary goals of preventing lower respiratory tract disease.

LONDON BROKER RATINGS: HSBC says 'buy' AstraZeneca but 'reduce' GSK

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday: